Dianthus Therapeutics (DNTH) Change in Accured Expenses (2017 - 2023)

Dianthus Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$1.7 million for Q2 2023.

• In Q2 2023, Change in Accured Expenses fell 169.82% year-over-year to -$1.7 million; the TTM figure through Jun 2023 stood at -$2.6 million (down 48.18% YoY), while the FY2022 annual figure was $973000.0, up 535.95% from the prior year.
• Change in Accured Expenses was -$1.7 million for Q2 2023 at Dianthus Therapeutics, up from -$3.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.7 million in Q4 2019 to a low of -$3.3 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$135444.4 across 5 years, with a median of -$260500.0 in 2020.
• The sharpest annual moves came in 2019 and 2023: Change in Accured Expenses jumped 643.89% in 2019, then tumbled 288.71% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $3.7 million in 2019, then sank by 93.13% to $255000.0 in 2020, then sank by 271.76% to -$438000.0 in 2021, then surged by 446.8% to $1.5 million in 2022, then tumbled by 210.66% to -$1.7 million in 2023.
• The last three Change in Accured Expenses figures came in at -$1.7 million (Q2 2023), -$3.3 million (Q1 2023), and $1.5 million (Q4 2022), per Business Quant data.